Jan'05 | Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow margin | (169.0%) | (525.8%) | (460.1%) | (331.8%) | (6,141.1%) | (922.8%) | (374.8%) | (144.2%) | (179.9%) | (430.3%) | (754.7%) | 0.0% | 523.1% | (59.7%) | (62.6%) | (2,504.7%) | (5,643.3%) | (4,029.5%) | (5,992.7%) | 0.0% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Free Cash Flow margin is 48,028.4%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Free Cash Flow margin for Summit Therapeutics Inc. have been 274.0% over the past three years, and (1,173.3%) over the past five years.
As of today, Summit Therapeutics Inc.'s Free Cash Flow margin is 48,028.4%, which is higher than industry median of (743.0%). It indicates that Summit Therapeutics Inc.'s Free Cash Flow margin is Good.